Albrecht, M.T., Li, H., Williamson, E.D., Lebutt, C.S., Flick-Smith, H.C., Quinn, C.P., Westra, H., Galloway, D., Mateczun, A., Goldman, S., Groen, H., Baillie, L.W. (2007). Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 75(11): 5425-33.
|
Baggett, H.C., Rhodes, J.C., Fridkin, S.K., Quinn, C.P., Hageman, J.C., Friedman, C.R., Dykewicz, C.A., Semenova, V.A., Romero-Steiner, S., Elie, C.M. and Jernigan, J.R. (2005) No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001. Clin Infect Dis 41(1 Oct), 991-997.
|
Biagini, R., Semenova, V.A., Li, H., Soroka, S.D., Fox, S. P., Boyer, A.E., Barr, J.R., Pirkle, J.L., Quinn, C.P. (2006). Serologic Approaches For Anthrax Diagnosis, Treatment & Vaccine Evaluation. Chemico-Biological Interactions 161(3), 183-184.
|
Biagini, R.E., R.E., Sammons, D.L., Smith, J.P., MacKenzie, B.A., Striley, C.A.F., Snawder, J.E., Robertson, S.E., Quinn, C.P. (2006). Rapid, Sensitive, and Specific Lateral-Flow Immunochromatographic Device To Measure Anti-Anthrax Protective Antigen Immunoglobulin G in Serum and Whole Blood. Clin Vacc Immunol 13 (5), 541-546.
|
Biagini, R.E., Sammons, D.L., Smith, J.P., MacKenzie, B.A., Striley, C.A.F., Semenova, V., Steward-Clark, E., Stamey, K., Freeman, A.E., Quinn, C.P. and Snawder, J.E. (2004). Comparison of a Multiplexed Fluorescent Covalent Microsphere Immunoassay (FCMIA) and an Enzyme-Linked Immunosorbent Assay (ELISA) for Measurement of Human IgG Antibodies to Anthrax Toxins. Clin Diag Lab Immunol 11(1):50-55.
|
Boyer, A.E., Quinn, C.P., Hoffmaster, A.E., Kozel, T.R., Saile, E., Marston, C.K., Percival, A., Plikaytis, B.D., Woolfitt, A.R., Gallegos, M., Sabourin, P., McWilliams, L.G., Pirkle, J.L., Barr, J.R. (2009). Kinetics of Lethal Factor and Poly-D-Glutamic Acid Antigenemia During Inhalation Anthrax in Rhesus Macaques. Infection and Immunity, 77(8):3432-41
|
Boyer, A.E., Quinn, C.P., Woolfitt, A.R., Pirkle, J.L., McWilliams, L.G., Stamey, K.L., Bagarozzi, D.A., Hart, J.C. Jr., Barr, J.R. (2007). Detection and Quantification of Anthrax Lethal Factor in Serum by Mass Spectrometry. Anal Chem 79(22):8463-70.
|
Brahmbhatt, T.N., B.K. Janes, E.S. Stibitz, S.C. Darnell, P. Sanz, S.B. Rasmussen, and A.D. O’Brien. 2007. Bacillus anthracis exosporium protein BclA affects spore germination, interaction with extracellular matrix proteins, and hydrophobicity. Infect. Immun. 75:5233-5239. PubMed Central ID: PMC2168272
|
Brahmbhatt, T.N., S.C. Darnell, H.M. Carvalho, P. Sanz, T.J. Kang, R.L. Bull, S.B. Rasmussen, A.S. Cross, and A.D. O’Brien. 2007. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect. Immun. 75:5240-5247. PubMed Central ID: PMC2168312
|
Budzik JM, Marraffini LA, Schneewind O. Assembly of pili on the surface of Bacillus cereus vegetative cells. Mol Microbiol. 2007 Oct;66(2):495-510.PMID: 17897374
|
Budzik JM, Oh SY, Schneewind O. Sortase D forms the covalent bond that links BcpB to the tip of Bacillus cereus pili. J Biol Chem. 2009 May 8;284(19):12989-97. Epub 2009 Mar 5.PMID: 19269972
|
Comer JE, Chopra AK, Peterson JW, Konig R. Direct Inhibition of T-Lymphocyte Activation by Anthrax Toxins In Vivo. Infection and Immunity. December 2005; 73(12): 8275-8281.
|
Comer JE, Galindo CL, Zhang Fan, Wenglikowski AM, Bush KL, Garner HR, Peterson JW, Copra AK. Murine Macrophage Transcriptional and Functional Responses to Bacillus Anthracis Edema Toxin. Microbial Pathog. (in press); 2006.
|
Comer JE, Noffsinger DM, McHenry DJ, Weisbaum DM, Chatuev GM, Chopra AK, Peterson JW. Evaluation of the Protective Effects of Quinacrine Against Bacillus Anthracis AMES.
J Toxicology and Environmental Health, Part A, 2006; 69:1083-1095.
|
Cybulski, R.J., Jr., P. Sanz, and A.D. O’Brien. 2010. Anthrax vaccination strategies. Molecular Aspects Medicine. 30:490-502.
|
Cybulski, R.J., Jr., P. Sanz, D. McDaniel, S. Darnell, R.L. Bull, and A.D. O’Brien. 2008. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Vaccine. 26:4927-4939.
|
Cybulski, R.J., P. Sanz, F. Alem, S. Stibitz, R.L. Bull, and A. D. O’Brien. 2009. Four superoxide dismutases contribute to Bacillus anthracis virulence and provide spores with redundant protection from oxidative stress. Infect Immun. 77: 274-285.
|
During, R.L., Li, W., Hao, B., Koenig, J.M., Stephens, D.S., Quinn, C.P., Southwick, F.S. (2005) Anthrax lethal toxin paralyzes neutrophil actin-based motility. J Infect Dis. 192(5), 837-45.
|
JF Kuhn, P Hoerth, ST Hoehn, T Preckel, KB Tomer. Proteomics Study of Anthrax Lethal Toxin-treated Murine Macrophages. Electrophoresis. 2006 Apr; 27(8):1584-97.
|
Laughlin, EM, Miller, JD, James E, Fillos, Dimitry, Ibegbu, CC, Mittler, R, Akondy, R, Kwok, William, Ahmed R, and Nepom G. (2006). Antigen-Specific CD4+T Cells Recognize Epitopes of Protective Antigen Following AVA Vaccination. Infection and Immunology, submitted for publication.
|
Li, H., Soroka, S.D., Taylor, T.H., Stamey, K.L., Stinson, K.W., Freeman, A.E., Abramson, D.R., Desai, R., Cronin, L.X., Oxford, J.W., Caba, J., Pleatman, C., Pathak, S., Schmidt, D.S., Semenova, V.A., Martin, S.K., Wilkins, P.P., Quinn C.P. (2008) Standardized, Mathematical Model-Based and Validated In Vitro Analysis of Anthrax Lethal Toxin Neutralization. J Immunol Methods 333:89–106.
|
Lixin Xu, Hui Fang, and David M. Frucht. (2008) Anthrax Lethal Toxin Increases Superoxide Production Capacity in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways. Journal of Immunology 180:4139.
|
Marano, N., Plikaytis, B.D., Martin, S.W., Rose, C., Semenova, V.A., Martin, S.K., Freeman, A.E., Li, H., Mulligan, M.J., Parker, S.D., Babcock, J., Keitel, W., El Sahly, H., Poland, G.A., Jacobson, R.M., Keyserling, H.L., Soroka, S.D., Fox, S.P., Stamper, J.L., McNeil, M.M., Perkins, B.A., Messonnier, N., and Quinn, C.P. (2008). Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months. JAMA 300(13):1532-1543.
|
McGowen, A. L., Hale, L. P., Shelburne, C. P., Abraham, S.N. and Staats, H.F. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine. 27:3544-52, 2009.
|
Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. Human Monoclonal Anti-protective Antigen Antibody Completely Protects Rabbits and is Synergistic with Ciprofloxacin in Protecting Mice and Guinea Pigs Against Inhalation Anthrax. Infect Immun. 2006 Feb; 74(2): 1016-24.
|
Quinn, C.P., Dull, P.M., Semenova, V., Li, H., Crotty, S., Taylor, T.H., Steward-Clark, E., Stamey, K.L., Schmidt, D.S., Wallace Stinson, K., Freeman, A.E., Elie, C.M., Martin, S.K., Greene, C., Aubert, R.D., Glidewell, J., Perkins, B.A., Ahmed, R., Stephens, D.S.(2004) Immune responses to Bacillus anthracis protective antigen in individuals with bioterrorism-associated cutaneous and inhalation anthrax. J Infect Dis 190(7), 1228-36.
|
Rollins, S.M., Peppercorn, A., Young, J.S., Drysdale, M., Baresch, A., Bikowski, M.V., Ashford, D.A., Quinn, C.P. et al. (2008) Application of In Vivo Induced Antigen Technology (IVIAT) to Bacillus anthracis. PLoS ONE 3(3): e1824 doi:10.1371/journal.pone.0001824.
|
Sanz, P., L.D. Teel, F. Alem, H.M.Carvalho, S.C. Darnell, and A.D. O’Brien. 2008. Detection of Bacillus anthracis spore germination in vivo by bioluminescence imaging. Infect Immun. 76:1036-1047. PubMed ID: 18195028
|
Sapra R, Gaucher SP, Lachmann JS, Buffleben GM, Chirica GS, Comer JE, Peterson JW, ChopraAK, SinghAK. Proteomic Analyses of Murine Macrophages Treated with Bacillus anthracis Lethal Toxin. Microb Pathog. 2006 Oct-Nov; 41(4-5):157-67. Epub 2006 Sep 1.
|
Semenova, V.A., Schmidt, D.S., Taylor, T.H. Jr, Li, H., Steward-Clark, E., Soroka, S.D., Ballard, M.M., Quinn, C.P. (2007). Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax. Vaccine 25(10):1780-8.
|
Sloat BR, DS Shaker, UM Le, ZR Cui, Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol. Med. Microbiol. (2008) 52(2):169-179.
|
Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies Virus Glycoprotein as a Carrier for Anthrax Protective Antigen. ScienceDirect. July 2006; Virology 353:344-356.Srinivasan KN, Brusic V and August JT. New Technologies for Vaccine Development. Drug Dev Res, 62:387-396, 2004.
|
Staats, H.F., S. M. Alam, R. M. Scearce, S. M. Kirwan, J. X. Zhang, W. M. Gwinn and B. F. Haynes. In vitro and In vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies After Passive Transfer in a Mouse Lethal Toxin Challenge Model to Define Correlates of Immunity. Infection and Immunity, 75: 5443-5452, 2007.
|
Szarowicz, S.E., During, R.L., Li, W., Quinn, C.P., Tang, W-J. and Southwick, F.S. Bacillus anthracis Toxins Paralyze Neutrophil Actin-based Motility. (2009). Infection and Immunity; 77(6): 2455-2464.
|
Walsh, J.J., Pesik, N., Quinn, C.P., Urdaneta, V., Dykewicz, C.D., Boyer, A.E., Guarner, J., Wilkins, P., Norville, K.J., Barr, J.R., Zaki, S.R., Patel, J.B., Reagan, S.P., Pirkle, J.L., Treadwell, T.A., Rosenstein Messonnier, N., Rotz, L.D., Meyer, R.F., Stephens, D.S. (2007). A case of naturally acquired inhalation anthrax: clinical care and analyses of anti–protective antigen immunoglobulin G and lethal factor. Clinical Infectious Diseases 44(7):968–971.
|
Williamson, E.D., Hodgson, I., Walker, N.J., Topping, A.W., Duchars, M.G., Mott, J.M., Estep, J., Lebutt, C., Flick-Smith, H.C., Jones, H.E., Li, H., Quinn, C.P. (2005) Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 73(9), 5978-87.
|
|